BRAF and non-small cell lung carcinoma: In patients with metastatic BRAFV600E mutant NSCLC, 59 patients were enrolled in a phase II study investigating combination pathway blocking with dabrafenib (a BRAF inhibitor) and trametinib (a MEK inhibitor).